Methods of treating ovarian cancer
AssigneeTesaro, Inc.
InventorsMary Lynne Hedley, Robert Martell
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of administering a PARP inhibitor to a cancer patient.
Claims19
A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, comprising
- administering daily to said patient an oral dose of niraparib equivalent to 200 mg or 300 mg of niraparib free base,
- wherein the patient has undergone at least one cycle of platinum-based chemotherapy;
- and
- wherein the patient carries no germline or somatic mutation in BRCA1 or BRCA2 genes and the cancer has no homologous recombination deficiency.
A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, the method comprising administering daily to said patient an oral dose of niraparib, wherein the patient is HRD negative and wherein the patient has undergone at least one cycle of platinum-based chemotherapy.
A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, consisting of
- administering daily to said patient an oral dose of niraparib equivalent to 200 mg or 300 mg of niraparib free base,
- wherein the patient has undergone at least one cycle of platinum-based chemotherapy;
- and
- wherein the patient carries no germline or somatic mutation in BRCA1 or BRCA2 genes and the cancer has no homologous recombination deficiency.
A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, the method consisting of administering daily to said patient an oral dose of niraparib, wherein the patient is HRD negative and wherein the patient has undergone at least one cycle of platinum-based chemotherapy.
Dependencies are inferred from the claim text.